Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies
Contact us

News

Stay up to date with the exciting new developments as we continue to grow.

The content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.

Filter by date

29 Aug 2019

Investor presentations

Shield Therapeutics plc, announces that the Company will be presenting at the following investor forums, providing an opportunity for investors to hear about the progress…

7 Aug 2019

Interim Report for the six months ended 30 June 2019

Shield Therapeutics plc, announces its unaudited interim results for the six months ended 30 June 2019. For further details please click here.

26 Jul 2019

FDA approves Feraccru® with a broad label of treating iron deficiency in adults

For further details please click here.

13 Jun 2019

Result of Shield Therapeutics plc – 2019 AGM

Shield Therapeutics plc, announces the results of the proxy vote for each of the resolutions set out in the Notice of AGM. Further details can…

3 Jun 2019

Shield Therapeutics plc – Update on legal proceedings

Shield Therapeutics plc, announces an update on legal proceedings with Teva Pharmaceutical Industries Ltd (TEVA). For further details please click here.

8 May 2019

Appointment of Joint Broker

Shield Therapeutics plc, announces the appointment of finnCap Ltd as its joint broker with immediate effect. For further details please click here.

30 Apr 2019

2018 Annual Report and 2019 AGM Notice

Shield Therapeutics plc, announces that the following documents have been sent to shareholders: ·     Annual Report and Accounts for the year ended 31 December 2018…

24 Apr 2019

Feraccru® granted major extension to approval in Switzerland

Shield Therapeutics plc, announces that the Swiss Agency for Therapeutic Products (Swissmedic) has approved a major extension of the approved indication for Feraccru® to now…

3 Apr 2019

Preliminary Results for the Year Ended 31 December 2018

Shield Therapeutics plc, announces its preliminary Group results for the year ended 31 December 2018. For full details click here.